HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

Benzinga · 1d ago
HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.